Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 15, 2022
Author's Reply
Dony Patel, Anke van Engen, Joseph Kim
BMC Urology
|
May 10, 2015
Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia
Jameel Nazir, Lars Heemstra, Anke van Engen, et al.
Journal of Market Access & Health Policy
|
February 24, 2025
The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?
Sian Tanner, Rebecca Coady, Ana Lisica, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
December 20, 2017
"De-escalation" strategy using micafungin for the treatment of systemic <i>Candida</i> infections: budget impact in France and Germany
Anke van Engen, Montserrat Casamayor, Soyoung Kim, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
February 27, 2009
Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany
Matthias Augustin, Marc Radtke, Anke van Engen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 11, 2024
The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment
Anke van Engen, Robert Krüger, Adam Parnaby, et al.
Journal of Health Economics and Outcomes Research
|
September 4, 2023
Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
Anke van Engen, Montserrat Casamayor, Fidelma Loftus, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2021
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials
Dony Patel, Fiona Grimson, Elena Mihaylova, et al.
Journal of Medical Economics
|
September 6, 2013
De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections
Robert G Masterton, Montserrat Casamayor, Primrose Musingarimi, et al.
Future Oncology (London, England)
|
September 2, 2022
A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology
Olivier Chassany, Anke van Engen, Livia Lai, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 15, 2022
Author's Reply
Dony Patel, Anke van Engen, Joseph Kim
BMC Urology
|
May 10, 2015
Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia
Jameel Nazir, Lars Heemstra, Anke van Engen, et al.
Journal of Market Access & Health Policy
|
February 24, 2025
The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?
Sian Tanner, Rebecca Coady, Ana Lisica, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
December 20, 2017
"De-escalation" strategy using micafungin for the treatment of systemic <i>Candida</i> infections: budget impact in France and Germany
Anke van Engen, Montserrat Casamayor, Soyoung Kim, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
February 27, 2009
Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany
Matthias Augustin, Marc Radtke, Anke van Engen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 11, 2024
The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment
Anke van Engen, Robert Krüger, Adam Parnaby, et al.
Journal of Health Economics and Outcomes Research
|
September 4, 2023
Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
Anke van Engen, Montserrat Casamayor, Fidelma Loftus, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2021
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials
Dony Patel, Fiona Grimson, Elena Mihaylova, et al.
Journal of Medical Economics
|
September 6, 2013
De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections
Robert G Masterton, Montserrat Casamayor, Primrose Musingarimi, et al.
Future Oncology (London, England)
|
September 2, 2022
A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology
Olivier Chassany, Anke van Engen, Livia Lai, et al.
Page
of 1